Novostat caps. 20mg 30 pc


Novostat caps. 20mg 30 pc



Active substance:
1 tablet contains: in terms of atorvastatin – 10, 20 or 40 mg.
Product form:
Capsules 10 mg, 20 mg, 40 mg and 80 mg. 10, 20, 30 capsules in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60 or 100 capsules in polymeric jars for medicaments. One jar or 1, 2, 3, 4, 5, 6, 9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack). Equipment is allowed to 2 or 3 cartons (packs) in multipacks (transportation) of paperboard for consumer packaging.
Hypersensitivity to any component of the drug. Active liver disease or increased activity “liver” transaminases in the blood plasma of unclear origin by more than 3-fold compared with the upper limit of normal (ULN). Age 18 years (insufficient clinical data on the efficacy and safety of the drug in this age group). Use in women of reproductive age who do not use adequate contraceptive methods. Pregnancy, lactation. Lactose intolerance, lactase deficiency, a syndrome of glucose-galactose malabsorption.
20 mg
– primary hypercholesterolemia (heterozygous familial and non-family hypercholesterolemia (type IIa classification Fredrickson) – Combination (mixed) hyperlipidaemia (type IIa and IIb Fredrickson classification) – Disbetalipoproteinemiya (Type III according to the classification Fredrickson) (as a supplement to the hypolipidemic diet) – family endogenous hypertriglyceridemia (type IV classification Fredrickson), resistant to hypolipidemic diet – Homozygous familial hypercholesterolemia with lack of effectiveness dietotera FDI and other non-pharmacological treatments – Primary prevention of cardiovascular complications in patients without clinical evidence of coronary heart disease, but having a few factors in its risk: age over 55 years, nicotine addiction, hypertension, diabetes, low levels of HDL-C plasma, genetic predisposition, including the background of dyslipidemia; – Secondary prevention of cardiovascular events in patients with coronary heart disease to reduce to mmarnogo in mortality, myocardial infarction, stroke, rehospitalization for angina and the need for revascularization procedures.
pharmachologic effect
Pharmacological group:
Lipid-lowering drugs – HMG-CoA reductase.
Pharmacological properties:
A synthetic lipid-lowering agent. Atorvastatin – selective competitive inhibitor Z-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), a key enzyme that converts 3-hydroxy-Z-methylglutaryl-CoA to mevalonate – a precursor of sterols, including cholesterol. In patients with homozygous and heterozygous familial hypercholesterolemia, non-family forms of hypercholesterolemia and mixed dyslipidemia, atorvastatin reduces the concentration of total cholesterol plasma levels (TC), low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo-B), and lipoprotein cholesterol is very low density (VLDL-cholesterol) and triglycerides (TG) causes unstable raising high density lipoprotein cholesterol concentration (HDL-C). Atorvastatin decreases the concentration of cholesterol in blood plasma lipoproteins by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of “liver” LDL receptors on the cell surface, which leads to increased trapping and catabolism of LDL-C. Atorvastatin reduces the formation of LDL-C and the number of LDL particles, causes a marked and sustained increase in the activity of LDL-receptors in combination with favorable qualitative changes in LDL particles, but also reduces the concentration of LDL-C in patients with homozygous hereditary familial hypercholesterolemia resistant to therapy other hypolipidemic means.
Conditions of supply of pharmacies
Dosing and Administration
Inside. Taken at any time of the day regardless of the meal. Before the start of treatment should be to try to get control of hypercholesterolemia with diet, exercise and weight loss in obese patients, as well as treatment of the underlying disease. In appointing the drug to the patient should be advised to standard hypocholesterolemic diet, which he must adhere to throughout the treatment period. The dose ranges from 10 mg to 80 mg 1 time per day and titrated with the initial content-LDL cholesterol, the goals of therapy and individual effect on the therapy. The maximum daily dose for single dose is 80 mg.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review